title: [Quality of life of patients with asthma on beclomethasone/formoterol. Cost-utility analysis].
abstract: OBJECTIVE
  To perform a cost-utility analysis on asthmatic patients on beclomethasone/formoterol fixed combination in Primary Health Care. Material and methods Non-probability sampling was used to select a group of asthmatic patients with moderate/severe persistent severity (GEMA 2009), treated with beclomethasone/formoterol fixed combination, over 18 years, had given their informed consent. The study observation period was 6 months. The variables studied were: age, sex, duration of disease, health resources used, analysis of health related quality of life by EQ-5D and SF-36, and the specific Asthma Quality of Life Questionnaire. For the qualitative variables, the frequency and percentages were calculated, and for the quantitative variables, the mean, SD and 95% CI. Chi-square, Student t-test and ANOVA were used for statistical inference. Comparisons were made with a statistical significance of 0.05.
  
  
  RESULTS
  Of the 64 patients that completed the study, 59.4% were female. The mean age was 49 years, and mean disease duration was 93 months. For asthma control, 53% of patients had a prescription pattern of one/12h. All health related quality of life scales were modified with respect to the baseline and the differences were statistically significant. Our patients had a better health related quality of life than Spanish asthma cohort. The incremental cost utility beclomethasone/formoterol versus usual treatment option was € 6,256/QALY.
authors.affiliation: Cátedra de Economía de la Salud y Uso Racional del Medicamento, Departamento de Farmacología y Terapéutica Clínica, Facultad de Medicina, Universidad de Málaga. Electronic address: ajgr@uma.es.
authors.forename: A J
authors.initials: AJ
authors.lastname: García-Ruiz
authors.affiliation: Grupo Respiratorio SEMERGEN.
authors.forename: J A
authors.initials: JA
authors.lastname: Quintano Jiménez
authors.affiliation: Cátedra de Economía de la Salud y Uso Racional del Medicamento, Departamento de Farmacología y Terapéutica Clínica, Facultad de Medicina, Universidad de Málaga.
authors.forename: N
authors.initials: N
authors.lastname: García-Agua Soler
authors.affiliation: Grupo Respiratorio SEMERGEN.
authors.forename: L
authors.initials: L
authors.lastname: Ginel Mendoza
authors.affiliation: Grupo Respiratorio SEMERGEN.
authors.forename: A
authors.initials: A
authors.lastname: Hidalgo Requena
authors.affiliation: Departamento de Relaciones Institucionales , Chiesi, España.
authors.forename: F
authors.initials: F
authors.lastname: Del Moral
mesh_terms: D000328:Adult; D000368:Aged; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage* / Q000191:economics; D001249:Asthma / Q000188:drug therapy* / Q000191:economics; D001507:Beclomethasone / Q000008:administration & dosage* / Q000191:economics; D003362:Cost-Benefit Analysis; D004338:Drug Combinations; D005260:Female; D000068759:Formoterol Fumarate / Q000008:administration & dosage* / Q000191:economics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011320:Primary Health Care; D011788:Quality of Life; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D004338:Drug Combinations; D001507:Beclomethasone; D000068759:Formoterol Fumarate
keywords: Análisis coste-utilidad; Asma; Asthma; Beclometasona; Beclomethasone; Calidad de vida; Cost-utility analysis; Farmacoeconomía; Formoterol; Pharmacoeconomics; Quality of life